Two phase 3 trials of adalimumab for hidradenitis suppurativa
AB Kimball, MM Okun, DA Williams… - … England Journal of …, 2016 - Mass Medical Soc
Background Hidradenitis suppurativa is a painful, chronic inflammatory skin disease with
few options for effective treatment. In a phase 2 trial, adalimumab, an antibody against tumor …
few options for effective treatment. In a phase 2 trial, adalimumab, an antibody against tumor …
Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial
AB Kimball, F Kerdel, D Adams, U Mrowietz… - Annals of internal …, 2012 - acpjournals.org
Chinese translation Background: Hidradenitis suppurativa (HS) is a chronic, painful skin
disease characterized by abscesses, nodules, and draining fistulas in the axilla and groin of …
disease characterized by abscesses, nodules, and draining fistulas in the axilla and groin of …
A prospective open‐label clinical trial of adalimumab for the treatment of hidradenitis suppurativa
M Amano, A Grant, FA Kerdel - International journal of …, 2010 - Wiley Online Library
Objective To evaluate the safety and efficacy of adalimumab for the management of
hidradenitis suppurativa (HS). Methods In a prospective open‐label phase II study …
hidradenitis suppurativa (HS). Methods In a prospective open‐label phase II study …
A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa
RA Lee, E Dommasch, J Treat, J Sciacca-Kirby… - Journal of the American …, 2009 - Elsevier
BACKGROUND: Medical therapies for hidradenitis suppurativa (HS) are often ineffective.
Tumor necrosis factor-α inhibitors may be a potential treatment for patients with moderate to …
Tumor necrosis factor-α inhibitors may be a potential treatment for patients with moderate to …
An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa
KS Leslie, SV Tripathi, TV Nguyen, M Pauli… - Journal of the American …, 2014 - Elsevier
Background Hidradenitis suppurativa (HS) is a chronic inflammatory disorder characterized
by sterile abscesses and fistulae predominantly affecting the axillae and groin. Various …
by sterile abscesses and fistulae predominantly affecting the axillae and groin. Various …
Adalimumab (antitumour necrosis factor‐α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study
HH Van der Zee, JD Laman, L de Ruiter… - British Journal of …, 2012 - academic.oup.com
Background Hidradenitis suppurativa (HS) is a difficult‐to‐manage disease. Randomized
controlled trials with antitumour necrosis factor (TNF)‐α biologics have been conducted and …
controlled trials with antitumour necrosis factor (TNF)‐α biologics have been conducted and …
Systematic review of immunomodulatory therapies for hidradenitis suppurativa
SYD Lim, HH Oon - Biologics: Targets and Therapy, 2019 - Taylor & Francis
Background: Greater understanding of the roles of tumor necrosis factor-α, IL-1β, IL-10, and
the IL-23/T-helper (Th) 17 and IL-12/Th1 pathways in immune dysregulation in …
the IL-23/T-helper (Th) 17 and IL-12/Th1 pathways in immune dysregulation in …
Long-term successful adalimumab therapy in severe hidradenitis suppurativa
R Blanco, VM Martínez-Taboada, I Villa… - Archives of …, 2009 - jamanetwork.com
Background Several studies report the use of tumor necrosis factor α (TNF-α) inhibitors in
refractory hidradenitis suppurativa (HS), particularly infliximab and etanercept. However …
refractory hidradenitis suppurativa (HS), particularly infliximab and etanercept. However …
A double‐blind placebo‐controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
I Miller, CD Lynggaard, S Lophaven… - British Journal of …, 2011 - academic.oup.com
Background Hidradenitis suppurativa (HS) has an impact on patients' quality of life.
Treatment of HS is generally unsatisfactory, thus new treatments are needed. Objectives To …
Treatment of HS is generally unsatisfactory, thus new treatments are needed. Objectives To …
Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review
T Montero-Vilchez, T Pozo-Román… - Journal of …, 2022 - Taylor & Francis
Background Hidradenitis suppurativa (HS) is a chronic debilitating autoinflammatory skin
disease. Adalimumab is the only biologic agent available to treat HS, but lack of response is …
disease. Adalimumab is the only biologic agent available to treat HS, but lack of response is …